1. V. Narla, M.J. Blaha, R.S. Blumenthal, E. D. Michos, “The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences,” Vasc. Health Risk Manag. vol. 5, pp.1033-1042, 2009.
2. İ. Arıkan, S. Metintaş, C. Kalyoncu, Z. Yıldız, “The Cardiovascular Disease Risk Factors Knowledge Level (CARRF-KL) Scale: a validity and reliability study,” Arch. Turk. Soc. Cardiol., vol. 37, pp. 35-40, 2009.
3. S. Civek, M. Akman, “Dünya ve Türkiye’de kardiyovasküler hastalıkların sıklığı ve riskin değerlendirilmesi,” The Journal of Turkish Family Physician, c.13, sayı 1, ss. 21-28, 2008.
4. N. Jain, R. Jain, H. Swami, D. K. Jain, “RP-HPLC Method for Simultaneous Estimation of Simvastatin and Ezetimibe in Bulk Drug and its Combined Dosage Form,” Asian J. Research Chem. vol.1, no.1, pp. 29-31, 2008.
5. M. Rahman, G. Parveen, N.K. Nyola, S. Khan, S.Talegaonkar, M. Shahar yar, R.K. Khar, “Simultaneus Estimation of Simvastatin and Ezetimibe in Pharmaceutical Tablet Dosage Forms by RP-HPLC: A Reviev,” International Journal of Pharma Research and Development, vol. 2, no. 9, pp. 56-62, 2010.